8-K: ChromaDex Rebrands as Niagen Bioscience, Signaling Focus on NAD+ Research and Healthy Aging

ChromaDex Corporation has officially changed its name to Niagen Bioscience, Inc., reflecting its commitment to advancing NAD+ research and healthy-aging solutions, with its stock trading under the new ticker symbol NAGE.

Summary

• ChromaDex Corporation has rebranded as Niagen Bioscience, Inc., effective March 19, 2025.
• The company's stock will trade on the Nasdaq Capital Market under the new ticker symbol NAGE starting March 19, 2025.
• The CUSIP number for the company's common stock remains unchanged.
• The rebrand highlights the company's focus on NAD+ research and its flagship ingredient, Niagen.
• Niagen Bioscience's mission is to advance healthspan and help people age better.
• The company offers Tru Niagen as a consumer supplement and Niagen Plus as a pharmaceutical-grade product available via prescription.
• Niagen Bioscience reported full-year 2024 net sales of $99.6 million, a 19% increase from the previous year, and holds $44.7 million in cash with no debt.
• The executive team will participate in the Nasdaq Closing Bell Ceremony on March 19, 2025, to mark the name change.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the rebranding, strong financial results, and focus on a growing market. The forward-looking statements and management's comments are optimistic, contributing to the high sentiment score.

Positives

• The company has a strong financial position with $44.7 million in cash and no debt.
• Full-year 2024 net sales increased by 19% to $99.6 million.
• Tru Niagen is the number one NAD+ boosting oral supplement in the United States.
• Niagen IV is rapidly being adopted and is available in over 475 wellness clinics.
• The company has a distinctive external research program.

Risks

• The company faces risks related to inflationary and adverse economic conditions.
• There are risks associated with operating losses and the need for additional financing.
• The company's success depends on maintaining and growing sales, marketing, and distribution capabilities.
• Changing consumer perceptions of the company's products could pose a risk.
• The company relies on a single or limited number of third-party suppliers.
• There are risks associated with conducting business in China.
• The company's ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner is a risk.
• The company's ability to obtain appropriate contracts with U.S. FDA-registered 503B outsourcing facilities is a risk.
• The company's ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B list is a risk.
• The company's ability to maintain and enforce its existing intellectual property and obtain new patents is a risk.
• Further research and development and the results of clinical trials may be unsuccessful.
• The ability to enroll sufficient numbers of subjects in clinical trials is a risk.
• Determinations made by the FDA and other governmental authorities could pose a risk.

Future Outlook

Niagen Bioscience aims to expand scientific discoveries and explore potential strategic partnerships in the bioscience and healthcare sectors, focusing on advancing healthspan and helping people age better.

Management Comments

• 'This transition is more than just a name change; it's a reflection of our identity and mission,' said Rob Fried, CEO of Niagen Bioscience.
• Rob Fried stated that as Niagen Bioscience, the company is more committed than ever to advancing healthspan and helping every living being around the world age better.
• Mr. Fried added that the new identity creates a stronger foundation for expanding scientific discoveries and opens doors for potential future strategic partnerships across the bioscience and healthcare sectors.
• Mr. Fried stated that with the name change, the company is celebrating that Niagen is a household name synonymous with healthy aging.

Industry Context

The announcement reflects a growing trend in the health and wellness industry towards personalized nutrition and preventative healthcare, with a focus on NAD+ boosting supplements and therapies. Niagen Bioscience aims to capitalize on this trend by solidifying its position as a leader in NAD+ research and product development.

Comparison to Industry Standards

• Niagen Bioscience's focus on NAD+ boosting positions it within a competitive landscape that includes companies like Elysium Health (Basis supplement) and Life Extension, which also offer NAD+ precursors.
• The company's dual approach of offering both consumer supplements (Tru Niagen) and pharmaceutical-grade products (Niagen Plus) differentiates it from competitors that primarily focus on one segment.
• The availability of Niagen IV in over 475 wellness clinics suggests a strong distribution network compared to companies that rely solely on online sales or retail partnerships.
• The reported $99.6 million in net sales for 2024 indicates a significant market presence, although a direct comparison to competitors' sales would be needed for a comprehensive assessment.

Stakeholder Impact

• Shareholders will see the company trading under a new ticker symbol, NAGE.
• Employees will be part of a company with a renewed focus on NAD+ research and healthy aging.
• Customers will continue to have access to Tru Niagen and Niagen Plus products.
• The company's suppliers and partners will continue to work with Niagen Bioscience under its new brand identity.
• Wellness clinics will continue to offer Niagen IV to their patients.

Next Steps

• The company will continue to focus on NAD+ research and product development.
• The company will explore potential strategic partnerships in the bioscience and healthcare sectors.
• The executive team will participate in the Nasdaq Closing Bell Ceremony on March 19, 2025.

Key Dates